Showing 1411-1420 of 1655 results for "".
- Alcon Survey Shows More Screen Time Causing Consumer Concern About Eye Health, Increasing Symptoms of Dry Eyehttps://modernod.com/news/alcon-survey-shows-more-screen-time-causing-consumer-concern-about-eye-health-increasing-symptoms-of-dry-eye/2478054/Alcon announced the results of a new survey, conducted by research firm Ipsos among 1,005 US adults, that uncover the impact the COVID-19 pandemic is having on consumers’ screen time and how that impacts their perceptions on eye health. Key findings include: Nearly 80% of Americans r
- GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients 3 Years After Lumevoq Treatmenthttps://modernod.com/news/gensight-biologics-reports-sustained-efficacy-and-safety-among-lhon-patients-3-years-after-lumevoq-treatment/2477972/GenSight Biologics reported that Leber Hereditary Optical Neuropathy (LHON) subjects treated with Lumevoq experienced sustained efficacy and safety 3 years after a single injection with the gene therapy. These findings come from CLIN06, the long-term follow-up study to which participants in the R
- AsclepiX Therapeutics Announces $35 Million Series A Financinghttps://modernod.com/news/asclepix-therapeutics-announces-35-million-series-a-financing/2477929/AsclepiX Therapeutics announced that it has closed a $35 million Series A financing to fund phase 1/2a clinical trials of AXT107, the company’s lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (AMD) and macular edema secondary to r
- Inovio Hints at Positive Early Phase 1 Safety Data for COVID-19 Vaccine INO-4800https://modernod.com/news/inovio-hints-at-positive-early-phase-1-safety-data-for-covid-19-vaccine-ino-4800/2477810/Inovio Pharmaceuticals suggested that preliminary safety data from an ongoing phase 1 trial indicates that its experimental COVID-19 DNA vaccine candidate INO-4800 appears to be safe in humans. “We are already seeing safety data and it has been benign,” commented R&D head K
- BVI Expands Portfolio with New Viscoelastic; Forges Strategic Partnership with Cromahttps://modernod.com/news/bvi-expands-portfolio-with-new-viscoelastic-forges-strategic-partnership-with-croma/2477789/BVI announced it has acquired the ophthalmic viscoelastic device (OVD) assets from Austrian-based Croma. In addition to the acquisition of existing products, BVI and Croma have embarked on an R&D collaboration on additional products that will come to market. Terms of the deal were not
- The Allergan Foundation Doubles its COVID-19 Response Donations to $4.0 Millionhttps://modernod.com/news/the-allergan-foundation-doubles-its-covid-19-response-donations-to-4-0-million/2477733/Allergan announced that The Allergan Foundation has fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic. The new grants double The Allergan Foundation’s total COVID-19 donations to date, r
- Market Scope: COVID-19 Fallout Could Reshape Ophthalmology in Indiahttps://modernod.com/news/market-scope-covid-19-fallout-could-reshape-ophthalmology-in-india/2477647/Market Scope estimates the total ophthalmic market in India in 2020 at $1.3 billion, with an optimistic assumption that the COVID-19 suspension of elective surgeries will last for 2 months or less. The firms forecasts a rapid return to 2019 levels of activity, resulting in an overall 25 percent r
- Nicox to Present NCX 470 Phase 2 Results at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/nicox-to-present-ncx-470-phase-2-results-at-glaucoma-360-new-horizons-forum/2477281/Nicox SA today announced that Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group, and General Manager of Nicox Ophthalmics, Inc, will present results from the NCX 470 Dolomites phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 N
- Vision Health Initiative Named a Mutual of America 2019 Community Partnership Award Winnerhttps://modernod.com/news/vision-health-initiative-named-a-mutual-of-america-2019-community-partnership-award-winner/2477094/Mutual of America announced that “Seeing the Future: Vision Health Initiative” was named a Merit Finalist award recipient of its 2019 Community Partnership Award competition. Seeing the Future: Vision Health Initiative was launched by Care For the Homeless (CFH) in 2016 after r
- Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Programhttps://modernod.com/news/lineage-cell-therapeutics-presents-encouraging-data-on-vision-restoration-program/2477041/Lineage Cell Therapeutics announced today that Igor Nasonkin, PhD, Principal Investigator and Director of R&D, served as a co-Chair of the Neural Differentiation, Transplantation, and Regeneration Nanosymposium, in addition to presenting data on the company’s Vision Restoration Program at Neu